HIRA criticized over Lipotor’s moderate price reduction

The Health Insurance Review and Assessment Service (HIRA)’s recent decision to make a moderate price reduction applied to Lipitor, the world's best-selling medicine made by Pfizer, has invited criticism from a lawmaker.

Rep. Park Eun-soo of the main opposition Democratic Party said that the HIRA has no strong will to save the nation’s ever-growing medication costs, despite the Ministry for H...